ClinicalTrials.gg

Program

GENSCI148

A development code. Also written as “GenSci148 Injection”.

Its studies are mostly in Retinal Vein Occlusion, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 1, since Sep 2, 20261 company-led study, 1 open or runningNext primary completion: Jun 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical11 open or runningphase 1since Sep 2, 2026Sep 2, 2026Jun 2028phase 1 · NCT07817615

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 2, 2026First study: phase 1 study in Retinal Vein OcclusionFirst studyNCT07817615 · 60 planned · China

Ahead

  1. Jun 2028Primary completion: phase 1 study in Retinal Vein OcclusionNCT07817615

TargetBeta

ANGPT2 →read by rule
“GenSci148 is a fusion protein that simultaneously targets VEGF-A, VEGF-C, VEGF-D, and Ang-2.”study text, by rule · the study

Other programs on ANGPT2

ProgramCompanyFurthest phaseStudies
faricimabruleHoffmann-La Rochephase 417

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07817615Retinal Vein Occlusion · China1Not yet recruitingJun 202860

How it is read

Names in the registry

  • “GenSci148 Injection”, 1 entry

Codes read as this program: GENSCI148.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.